Hoechst AG acquired the remaining shares of Marion Merrell Dow it did not already own for $7.1 billion ($25.75/share). The deal was structured in two steps: first acquiring Dow Chemical's 71% stake (~$5.1B), then the remaining public float. The combined entity became Hoechst Marion Roussel.
Key facts
AnnouncedMay 04, 1995
ClosedSep 30, 1995
Deal value$7.1B
Deal typeAcquisition/Merger
Therapeutic areaCardiovascular, Respiratory
IndicationsHypertension, Angina, Allergies
Key assetsCardizem (diltiazem), Seldane (terfenadine), US commercial infrastructure